Östgren, Carl Johan
Otten, Julia
Festin, Karin
Angerås, Oskar
Bergström, Göran
Cederlund, Kerstin
Engström, Gunnar
Eriksson, Maria J.
Eriksson, Mats
Fall, Tove
Gummesson, Anders
Hagström, Emil
Hellman, Urban
James, Stefan K.
Jernberg, Tomas
Kihlberg, Johan
Kylhammar, David
Markstad, Hanna
Nilsson, Peter
Persson, Anders
Persson, Margaretha
Pirazzi, Carlo
Renklint, Rebecka
Rosengren, Annika
Söderberg, Stefan
Sundström, Johan
Funding for this research was provided by:
Vetenskapsrådet (2021-06432, 2019-01471, 2018-02527)
Hjärt-Lungfonden (20210184, 2019-0505, 2021-03459)
European Research Council (ERC-2018-STG801965)
AFA Försäkring
Linköping University
Article History
Received: 3 March 2023
Accepted: 5 September 2023
First Online: 27 September 2023
Declarations
:
: The SCAPIS study was approved by the regional ethics committee in Umeå (Dnr 2010-228-31 M) and complied with the Declaration of Helsinki. Written informed consent was obtained from all participants.
: Not applicable.
: EH reports research grant funding from Sanofi-Aventis, Pfizer, Amgen, Swedish Heart and Lung foundation, and consulting or honoraria from Amgen, Sanofi-Aventis, Novartis, Amarin, and NovoNordisk. SS reports speakers’ honoraria from Actelion/J&J, support for attending the PAH Forum in Madrid as co-chair from Actelion/J&J and being a part of advisory boards for Actelion/J&J and Novartis. JS reports stocks in Anagram kommunikation AB and Symptoms Europe AB. SKJ reports being a part of a Data Safety Monitoring Board for New Holland (Obecetrapid study program) without personal payment. The rest of the authors declare no competing interests.